Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL312 Target Snapshot

Polyunsaturated fatty acid 5-lipoxygenase · SINGLE PROTEIN · Rattus norvegicus

2,113Compounds
305Assays
9Approved Drugs
2,221.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P12527. Use UniProt P12527 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P12527 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Polyunsaturated fatty acid 5-lipoxygenase as ChEMBL target CHEMBL312, mapped to UniProt P12527. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Polyunsaturated fatty acid 5-lipoxygenase
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL312
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P12527
Polyunsaturated fatty acid 5-lipoxygenase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Polyunsaturated fatty acid 5-lipoxygenase is the right protein anchor across sources, using UniProt P12527 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPolyunsaturated fatty acid 5-lipoxygenase
UniProt AccessionP12527
Component TypeProtein
Sequence Length673 aa

Polyunsaturated fatty acid 5-lipoxygenase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Polyunsaturated fatty acid 5-lipoxygenase, mapped to UniProt P12527. Sequence length is 673 aa.

Mapped IDP12527
Review namePolyunsaturated fatty acid 5-lipoxygenase
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

9
Approved
2
Phase III
20
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC502,220.0
KI1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL126838 8.62 IC50 2.4 Preclinical
CHEMBL125415 8.42 IC50 3.8 Preclinical
CHEMBL129590 8.4 IC50 4.0 Preclinical
CHEMBL341135 8.4 IC50 4.0 Preclinical
CHEMBL126669 8.38 IC50 4.2 Preclinical
CHEMBL2115381 8.37 IC50 4.3 Preclinical
CHEMBL128000 8.34 IC50 4.6 Preclinical
CHEMBL262892 8.33 IC50 4.7 Preclinical
CHEMBL114516 8.3 IC50 5.0 Preclinical
CHEMBL29097 8.3 IC50 5.0 Preclinical
Distribution

pChEMBL Value Distribution

314
5.0
417
5.5
427
6.0
252
6.5
166
7.0
72
7.5
27
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

Assay Landscape

Assay Landscape

306
Total Assays
1,442
Tested Compounds
2
Assay Types
Binding — 260 assays, 1,442 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 164 998 5.9
single protein format 51 241 5.8
assay format 38 191 6.2
organism-based format 4 7 6.6
tissue-based format 3 5 5.5
Functional — 46 assays, 289 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 20 100 5.5
cell-based format 19 175 5.9
organism-based format 4 0
tissue-based format 3 14 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine